Integrated Advisors Network LLC Has $17.17 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Integrated Advisors Network LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 13.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 65,769 shares of the medical instruments supplier's stock after buying an additional 7,616 shares during the quarter. Insulet accounts for approximately 0.8% of Integrated Advisors Network LLC's holdings, making the stock its 21st largest holding. Integrated Advisors Network LLC owned 0.09% of Insulet worth $17,170,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PODD. Baillie Gifford & Co. boosted its position in Insulet by 3.5% during the 4th quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after acquiring an additional 79,982 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Insulet by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 1,779,167 shares of the medical instruments supplier's stock valued at $463,347,000 after acquiring an additional 40,566 shares during the period. Norges Bank acquired a new position in shares of Insulet during the 4th quarter worth about $248,806,000. Artisan Partners Limited Partnership raised its holdings in shares of Insulet by 24.1% in the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after purchasing an additional 149,524 shares during the period. Finally, Northern Trust Corp lifted its stake in Insulet by 20.5% in the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock valued at $192,881,000 after purchasing an additional 125,710 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the topic of several research analyst reports. Oppenheimer upped their price objective on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Stifel Nicolaus lifted their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Royal Bank of Canada initiated coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price for the company. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, The Goldman Sachs Group started coverage on Insulet in a research report on Friday. They set a "buy" rating and a $380.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and an average target price of $313.78.

Insider Activity

In related news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president now owns 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Price Performance

Insulet stock traded up $0.66 during midday trading on Friday, reaching $324.51. The company's stock had a trading volume of 261,523 shares, compared to its average volume of 708,260. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market cap of $22.84 billion, a PE ratio of 56.19, a price-to-earnings-growth ratio of 3.62 and a beta of 1.26. Insulet Co. has a 52 week low of $172.07 and a 52 week high of $329.33. The business has a 50-day moving average price of $275.57 and a 200-day moving average price of $271.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm's quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.73 EPS. On average, sell-side analysts predict that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.